Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
Suzhou AsiFlyer Biotechnology Co., Ltd. announced that on August 1, 2026 it signed a technology...
Deals
Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA: 688621) and DeepMed Technology (Suzhou) Co., Ltd. have...
Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate
Liaocheng University and Shanghai Maiboxing Biotechnology Co., Ltd. have signed a cooperation agreement totaling RMB...
Clinical‑Stage Biopharma Revelyx Bio Launches with Exclusive Global License for YY003 – Ready‑to‑Use Recombinant Botulinum Toxin Type A
Clinical‑stage biopharmaceutical company Revelyx Bio, Inc. announced on August 31, 2026 its official launch, backed...
Eton Pharmaceuticals Licenses Auson’s Timolol Gel ASN001 for North America – Potential First Topical Therapy for Infantile Hemangioma in the U.S.
Auson Pharma (US), a wholly‑owned subsidiary of Shanghai Auson Pharmaceuticals, announced on August 6, 2026...
China Medical System Licenses Leios Therapeutics’ Injectable Fat‑Reduction Therapy 10XB‑101 in Greater China, Alongside Strategic Equity Investment
Leios Therapeutics, an innovative aesthetic therapies company, announced on August 31, 2026 that it has...
China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation
Panboron (Hainan) BNCT Hospital, a subsidiary of China Biotech Services Holdings Limited (HKG: 8037), officially...
Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018
Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced on September 8, 2026 the completion of...
HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems
HepaBio Therapeutics announced that it has raised tens of millions of RMB in Series A...
Insilico Medicine and MobiDrop Sign Strategic Partnership to Advance AI‑Ready Single‑Cell Data for Drug Discovery
Insilico Medicine (HKG: 3696) signed a strategic cooperation agreement with MobiDrop, under which the two...
Anglikang Pharmaceuticals Terminates Affinity Partnership for IMD‑1005, Novel Tumor Microenvironment‑Activated CD47 Antibody
Anglikang Pharmaceuticals (SHE: 002940) announced that its partnership with Affinity for the IMD‑1005 project will...
Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib
Xuanzhu Biopharmaceutical (HKG: 2575) announced that it has entered into a tripartite commercial agreement with...
Typewriter Therapeutics Raises USD 56 Million Series A to Advance TPRT RNA Gene Insertion Platform for In Vivo CAR-T and Liver Diseases
Typewriter Therapeutics announced the completion of a USD 56 million Series A financing to develop...
GenScript Proposes ProBio Spin-Off for Standalone Listing on HKEX Main Board
Genscript Biotech Corporation (HKG: 1548) announced that it proposes to spin off its indirect non-wholly-owned...
Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently
Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) China and Belief BioMed Inc. issued a...
NeuShen Therapeutics Closes Oversubscribed Series B Exceeding USD 80 Million to Accelerate Global CNS Pipeline
NeuShen Therapeutics announced the successful closing of an oversubscribed Series B financing round exceeding USD...
Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double‑Digit Royalties
Keymed Biosciences Inc. (HKG: 2162) announced that it has entered into an exclusive licensing agreement...
PegBio Signs R&D Collaboration with SN BioScience to Pair Three Innovative Peptide Candidates with SNA Long‑Acting Delivery for Metabolic Diseases
PegBio Co., Ltd. (HKG: 2565) announced that it has entered into a material transfer agreement...
Biocytogen Signs Non‑Exclusive Nanobody Licensing Deal with Qilu Pharmaceutical for Innovative Neurological Drug R&D
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315; SHA: 688796) announced that it has signed a...
Medtronic Invests USD 700 Million in Cornerstone Robotics, Wins Distribution Rights for Sentire Endoscopic Surgical Robot Outside the U.S.
Medtronic (NYSE: MDT) announced a strategic partnership with Cornerstone Robotics, including a strategic investment of...